Identification and relative contributions of human cytochrome P450 isoforms involved in the metabolism of glibenclamide and lansoprazole: evaluation of an approach based on the in vitro substrate disappearance rate

Reference

• BALDWIN, S. J., BLOOMER, J. C., SMITH, G. J., AYRTON, A. D., CLARKE, S. E. and CHENERY, R. J., 1995, Ketoconazole and sulphaphenazole as the respective selective inhibitors of P4503A and 2C9. Xenobiotica, 25, 261–270.
   PubMed Web of Science ®Google Scholar
• BOOBIS, A. R., MURRAY, S., HAMPDEN, C. E. and DAVIES, D. S., 1985, Genetic polymorphism in drug oxidation: in vitro studies of human debrisoquine 4-hydroxylase and bufuralol V-hydroxylase activities. Biochemical Pharmacology, 34, 65–71.
   PubMed Web of Science ®Google Scholar
• BROLY, F., LIBERSA, C., LHERMITTE, M., BECHTEL, P. and DUPUIS, B., 1989, Effect of quinidine on the dextromethorphan 0-demethylase activity of microsomal fractions from human liver. British Journal of Clinical Pharmacology, 28, 29–36.
   PubMed Web of Science ®Google Scholar
• CRESPI, C. L., 1995, Xenobiotic-metabolizing human cells as tools for pharmacological and toxicological research. Advances in Drug Research, 26, 179–235.
   Google Scholar
• GOLDSTEIN, J. A., FALETTO, M. B., ROMKES-SPARKS, M., SULLIVAN, T., KITAREEWAN, S., RAUCY, J. L., LASKER, J. M. and GHANAYEM, B. I., 1994, Evidence that CYP2C19 is the major (S)-mephenytoin 4'-hydroxylase in humans. Biochemistry, 33, 1743–1752.
   Google Scholar
• GUENGERICH, F. P., 1996, In vitro techniques for studying drug metabolism. Journal of Pharmacokinetics and Biopharmaceutics, 24, 521–533.
   PubMedGoogle Scholar
• GUENGERICH, F. P., Km, D. H. and IwAsAxi, M., 1991, Role of human cytochrome P-450 IIE1 in the oxidation of many low molecular weight cancer suspects. Chemical Research in Toxicology, 4, 168–179.
   PubMed Web of Science ®Google Scholar
• HEYN, H., WHITE, R. B. and STEVENS, J. C., 1996, Catalytic role of cytochrome P4502B6 in the N-demethylation of S-mephenytoin. Drug Metabolism and Disposition, 24, 948–954.
   PubMed Web of Science ®Google Scholar
• KATSUKI, H., NAKAMURA, C., ARIMORI, K., FUJIYAMA, S. and NAKANO, M., 1997, Genetic polymorphism of CYP2C19 and lansoprazole pharmacokinetics in Japanese subjects. European Journal of Clinical Pharmacology, 52, 391–396.
   PubMed Web of Science ®Google Scholar
• KOBAYASHI, K., MIMURA, N., FUJII, H., MINAMI, H., SASAKI, Y., SHIMADA, N. and CHIBA, K., 2000, Role of human cytochrome P450 3A4 in metabolism of medroxyprogesterone acetate. Clinical Cancer Research, 6, 3297–3303.
   PubMed Web of Science ®Google Scholar
• KRAUSZ, K. W., GOLDFARB, I., BUTERS, J. T. M., YANG, T. J., GONZALEZ, F. J. and GELBOIN, H. V., 2001, Monoclonal antibodies specific and inhibitory to human cytochromes P450 2C8, 2C9, and 2C19. Drug Metabolism and Disposition, 29, 1410–1423.
   Google Scholar
• LEEMANN, T., TRANSON, C. and DAYER, P., 1993, Cytochrome P450TB (CYP2C): a major monooxygenase catalyzing diclofenac 4'-hydroxylation in human liver. Life Science, 52, 29–34.
   PubMed Web of Science ®Google Scholar
• LIN, J. H. and Lu, A. H. Y., 1998, Inhibition and induction of cytochrome P450 and the clinical implications. Clinical Phrmacokinetics, 35, 361–390.
   PubMed Web of Science ®Google Scholar
• Lu, A. Y. H., WANG, R. W. and LIN, J. H., 2003, Cytochrome P450 in vitro reaction phenotyping: a re-evaluation of approaches used for P450 isoform identification. Drug Metabolism and Disposition, 31, 345–350.
   Google Scholar
• NAKAJIMA, M., NAKAMURA, S., TOKUDOME, S., SHIMADA, N., YAMAZAKI, H. and YOKOI, T., 1999, Azelastine N-demethylation by cytochrome P-450 (CYP)3A4, CYP2D6, and CYP1A2 in human liver microsomes: evaluation of approach to predict the contribution of multiple CYPs. Drug Metabolism and Disposition, 27, 1381–1391.
   PubMed Web of Science ®Google Scholar
• NARITOMI, Y., TERASHITA, S., KAGAYAMA, A. and SUGIYAMA, Y., 2003, Utility of hepatocytes in predicting drug metabolism: comparison of hepatic intrinsic clearance in rats and humans in vivo and in vitro. Drug Metabolism and Disposition, 31, 580–588.
   PubMed Web of Science ®Google Scholar
• NARITOMI, Y., TERASHITA, S., KIMURA, S., SUZUKI, A., KAGAYAMA, A. and SUGIYAMA, Y., 2001, Prediction of human hepatic clearance from in vivo animal experiments and in vitro metabolic studies with liver microsomes from animals and humans. Drug Metabolism and Disposition, 29, 1316–1324.
   PubMed Web of Science ®Google Scholar
• NIEMI, M., CASCORBI, I., Timm, R., KROEMER, H. K., NEUVONEN, P. J. and KwisTo K. T., 2002, Glyburide and glimepiride pharmacokinetics in subjects with different CYP2C9 genotypes. Clinical Pharmacology and Therapeutics, 72, 326–332.
   Google Scholar
• PEARCE, R. E., RODRIGUES, A. D., GOLDSTEIN, J. A. and PARKINSON, A., 1996, Identification of the human P450 enzymes involved in lansoprazole metabolism. Journal of Pharmacology and Experimental Therapeutics, 277, 805–816.
   PubMed Web of Science ®Google Scholar
• PETER, R., BOCKER, R., BEAUNE, P. H., IWASAKI, M., GUENGERICH, F. P. and YANG, C. S., 1990, Hydroxylation of chlorzoxazone as a specific probe for human liver cytochrome P-45011E1. Chemical Research in Toxicology, 3, 566–573.
   PubMed Web of Science ®Google Scholar
• RAHMAN, A., KORZEKWA, K. R., GROGAN, J., GONZALEZ, F. J. and HARRIS, J. W., 1994, Selective biotransformation of taxol to 6ce-hydroxytaxol by human cytochrome P450 2C8. Cancer Research, 54, 5543–5546.
   PubMed Web of Science ®Google Scholar
• SUZUKI, A., ImA, I., HIROTA, M., AKIMOTO, M., HIGUCHI, S., SUWA, T., TANI, M., ISHIZAKI, T. and CHIBA, K., 2003, CYP isoforms involved in the metabolism of clarithromycin in vitro: comparison between the identification from disappearance rate and that from formation rate of metabolites. Drug Metabolism and Pharmacokinetics, 18, 104–113.
   PubMedGoogle Scholar
• SUZUKI, A., ImA, I., TANAKA, F., AKIMOTO, M., FUKUSHIMA, K., TANI, M., ISHIZAKI, T. and CHIBA, K., 1999, Identification of human cytochrome P-450 isoforms involved in metabolism of R(+)- and S(—)-gallopamil: utility of in vitro disappearance rate. Drug Metabolism and Disposition, 27, 1254–1259.
   PubMed Web of Science ®Google Scholar
• SUZUKI, H., KNELLER, M. B., HAINING, R. L., TRAGER, W. F. and RETTIE, A. E., 2002, (±)-N-3-benzyl-nirvanol and (—)-N-3-benzyl-phenobarbital: new potent and selective in vitro inhibitors of CYP2C19. Drug Metabolism and Disposition, 30, 235–239.
   PubMed Web of Science ®Google Scholar
• TASSANEEYAKUL, W., BIRKETT, D. J., VERONESE, M. E., McMANus, M. E., TUKEY, R. H., QUATTROCHI, L. C., GELBOIN, H. V. and MINERS, J. 0., 1993, Specificity of substrate and inhibitor probes for human cytochromes P450 1A1 and 1A2. Journal of Pharmacology and Experimental Therapeutics, 265, 401–407.
   Google Scholar
• VAN GIERSBERGEN, P. L. M., TREIBER, A., CLOZEL, M., BODIN, F. and DINGEMANSE, J., 2002, In vivo and in vitro studies exploring the pharmacokinetic interaction between bosentan, a dual endothelin receptor antagonist, and glyburide. Clinical Pharmacology and Therapeutics, 71, 253–262.
   Google Scholar
• WALSKY, R. L. and OBACH, R. S., 2003, Verification of the selectivity of (+)N-3-benzylnirvanol as a CYP2C19 inhibitor. Drug Metabolism and Disposition, 31, 343.
   PubMed Web of Science ®Google Scholar
• WAXMAN, D. J., ATTISANO, C., GUENGERICH, F. P. and LAPENSON, D. P., 1988, Human liver microsomal steroid metabolism: identification of the major microsomal steroid hormone 613-hydroxylase cytochrome P-450 enzyme. Archives of Biochemistry and Biophysics, 263, 424–436.
   PubMed Web of Science ®Google Scholar
• YUN, C. H., SHIMADA, T. and GUENGERICH, F. P., 1991, Purification and characterization of human liver microsomal cytochrome P-450 2A6. Molecular Pharmacology, 40, 679–685.
   PubMed Web of Science ®Google Scholar